NASDAQ: RAPP - Rapport Therapeutics, Inc.

Rentabilidade por seis meses: -50.93%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Rapport Therapeutics, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

mais detalhes
The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2024-06-07
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.rapportrx.com
Цена ао 9.7
Alteração de preço por dia: +3.61% (9.7)
Alteração de preço por semana: +3.4% (9.72)
Alteração de preço por mês: -8.97% (11.04)
Alteração de preço em 3 meses: -47.19% (19.03)
Mudança de preço em seis meses: -50.93% (20.48)
Mudança de preço desde o início do ano: -43.35% (17.74)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 12.05 1
P/E 0 0
EV/EBITDA -43.63 0
Total: 0.625

Eficiência

Nome Significado Nota
ROA, % -33.3 0
ROE, % -35.09 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0178 10
Total: 9.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 0 0
Rentabilidade Ebitda, % 702.31 10
Rentabilidade EPS, % 29.66 4
Total: 6.8
Mais detalhes

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
iShares Neuroscience and Healthcare ETF 0.71137 19.72 0.03
iShares Micro-Cap ETF 0.04983 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00794 38.04 0.6026
0.2624.950.72



Supervisor Cargo Pagamento Ano de nascimento
Dr. Steven M. Paul M.D. Founder & Independent Chairman 1951 (74 ano)
Mr. Abraham N. Ceesay M.B.A. CEO, President, Treasurer & Director 1978 (47 anos)
Dr. Troy A. Ignelzi Chief Financial Officer 1968 (57 anos)
Ms. Cheryl Gault Chief Operating Officer 1979 (46 anos)
Mr. David Bredt M.D., Ph.D. Founder & Chief Scientific Officer 1965 (60 anos)
Ms. Karina Chmielewski Chief Information Officer & Head of Operations
Ms. Julie DiCarlo Head of Communications & Investor Relations
Ms. Kathleen A. Wilkinson Chief People Officer 1972 (53 ano)
Dr. Bradley S. Galer M.D. Chief Medical Officer 1962 (63 ano)
Mr. Swamy Yeleswaram Ph.D. Chief Development Officer 1963 (62 ano)

Endereço: United States, Boston, 1325 Boylston Street - abrir no Google Maps, abrir mapas Yandex
Site: https://www.rapportrx.com